Final safety results from ATHENA-MONO (GOG-3020/ENGOT-ov45), a randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer

被引：0
|
作者：
O'Malley, David M.
Monk, Bradley J.
Lim, Myong Cheol
Pradera, Jose Fuentes
Buscema, Joseph
Wilson, Michelle K.
De Vivo, Rocco
Herzog, Thomas J.
Zagouri, Flora
Oza, Amit M.
Mikheeva, Olga N.
Diaz, John Paul
Lisyanskaya, Alla Sergeevna
Morris, Robert
Bruchim, Ilan
Craib, Marcia
Connor, Christy
Shih, Danny
Fujiwara, Keiichi
Kristeleit, Rebecca
机构：
[1] Ohio State Univ, Div Gynecol Oncol, James Canc Ctr, Columbus, OH USA
[2] Creighton Univ, Univ Arizona, GOG Fdn, Coll Med,Sch Med, Phoenix, AZ USA
[3] Natl Canc Ctr Korea, Gynecol Oncol, Goyang Si, Gyeonggi Do, South Korea
[4] Hosp Univ Virgen Valme, Seville, Spain
[5] Arizona Oncol Associates, Tucson, AZ USA
[6] Auckland City Hosp, Dept Canc & Blood, Auckland, New Zealand
[7] Osped San Bortolo, Dept Med Oncol, Vicenza, Italy
[8] Univ Cincinnati, Cincinnati, OH USA
[9] Alexandra Hosp, Dept Clin Therapeut, Athens, Greece
[10] Princess Margaret Hosp Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[11] Ltd Liabil Co MedPomosch, St Petersburg, Russia
[12] Baptist Hlth South Florida, Miami Canc Inst, Miami, FL USA
[13] St Petersburg State Budget Healthcare Inst, City Clin Oncol Dispensary, St Petersburg, Russia
[14] Wayne State Univ, Karmanos Canc Inst, Div Gynecol Oncol, Dept Oncol,Sch Med, Detroit, MI USA
[15] Rappaport Fac Med, Hillel Yaffe Med Ctr, Hadera, Israel
[16] Pharma&, Stat Programming, New York, NY USA
[17] Pharma&, Clin Operat, New York, NY USA
[18] Saitama Med Univ Int Med Ctr, Dept Gynecol Oncol, Hidaka, Saitama, Japan
[19] Guys & St Thomas NHS Fdn Trust, Dept Oncol, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5554
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO/PACLITAXEL-CONTROLLED STUDY OF BATIRAXCEPT IN COMBINATION WITH WEEKLY PACLITAXEL IN PATIENTS WITH PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (GOG-3059/ENGOT OV-66)
    Fuh, Katherine
    Moore, Kathleen
    Baert, Thais
    Herzog, Thomas
    Cibula, David
    Liu, Joyce
    Eberst, Laurianne
    Lewin, Sharon
    Secord, Angeles Alvarez
    Sehouli, Jalid
    Myers, Tashanna
    Bamias, Aristotelis
    Rimel, B. J.
    Colombo, Nicoletta
    Franke, Amy
    Shoop, Dipti
    De Giorgi, Ugo
    Pikiel, Joanna
    Bowen, Rebecca
    Gonzalez-Martin, Antonio
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A234 - A235
  • [42] LINZAGOLIX FOR ENDOMETRIOSIS-ASSOCIATED PAIN: SAFETY RESULTS FROM EDELWEISS 3, A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Donnez, J.
    Taylor, H.
    Gemzell-Danielsson, K.
    Catherino, W.
    Bestel, E.
    Gotteland, J. P.
    Humberstone, A.
    Moore, L.
    Garner, E.
    HUMAN REPRODUCTION, 2022, 37 : I111 - I111
  • [43] Fuzuloparib maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer: a multicenter, randomized, double-blind, placebo-controlled, phase III trial
    Li, Ning
    Zhang, Youzhong
    Wang, Jing
    Zhu, Jianqing
    Wang, Li
    Wu, Xiaohua
    Yao, Desheng
    Wu, Qiang
    Liu, Jihong
    Tang, Junying
    Yin, Rutie
    Zhang, Guonan
    Lou, Ge
    An, Ruifang
    Xia, Xiaoping
    Li, Qingshui
    Zhu, Yaping
    Hong, Zheng
    Yang, Xinfeng
    Hu, Yuanjing
    Zhang, Xin
    Wan, Xiaoyun
    Qu, Jing
    Zhang, Ben
    Wu, Lingying
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S57 - S58
  • [44] Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer
    Ray-Coquard, Isabelle
    Cibula, David
    Mirza, Mansoor R.
    Reuss, Alexander
    Ricci, Caterina
    Colombo, Nicoletta
    Koch, Horst
    Goffin, Frederic
    Gonzalez-Martin, Antonio
    Ottevanger, Petronella B.
    Baumann, Klaus
    Bjorge, Line
    Lesoin, Anne
    Burges, Alexander
    Rosenberg, Per
    Gropp-Meier, Martina
    Harrela, Maija
    Harter, Philipp
    Frenel, Jean-Sebastien
    Minarik, Tomas
    Pisano, Carmela
    Hasenburg, Annette
    Merger, Michael
    du Bois, Andreas
    Kristensen, Gunnar
    Bidzinski, Mariusz
    Helpianska, Lydia
    Kutarska, Elzbieta
    Flynn, Patrick
    Hils, Rita
    Malander, Susanne
    Scambia, Giovanni
    Tredan, Olivier
    Bamias, Aristotelis
    Wimberger, Pauline
    Joly, Florence
    Abu-Khalaf, Maysa
    Lisyanskaya, Alla
    Vergote, Ignace
    Pippitt, Charles H.
    Fiane, Bent
    Teneriello, Michael
    Janni, Wolfgang
    Rushing, Scott
    Herwig, Uwe
    Ghamande, Sharad
    Nicoletto, Maria Ornella
    Pfisterer, Jacobus
    Peters, Martin
    Tewari, Krishnansu
    INTERNATIONAL JOURNAL OF CANCER, 2020, 146 (02) : 439 - 448
  • [45] EFFICACY AND SAFETY OF INCOBOTULINUMTOXINA IN THE TREATMENT OF UPPER FACIAL LINES: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY
    Kerscher, Martina
    Rzany, Berthold
    Prager, Welf
    Trevidic, Patrick
    Inglefield, Christopher
    TOXICON, 2018, 156 : S60 - S60
  • [46] Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy plus /- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)
    Moore, K. N.
    Bookman, M.
    Sehouli, J.
    Miller, A.
    Anderson, C.
    Scambia, G.
    Myers, T.
    Taskiran, C.
    Robison, K.
    Maenpaa, J.
    Willmott, L. J.
    Colombo, N.
    Thomes-Pepin, J.
    Gold, M. A.
    Aghajanian, C.
    Wu, F.
    Molinero, L.
    Khor, V.
    Lin, Y. G.
    Pignata, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S1161 - S1162
  • [47] Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
    Poveda, Andres
    Floquet, Anne
    Ledermann, Jonathan A.
    Asher, Rebecca
    Penson, Richard T.
    Oza, Amit M.
    Korach, Jacob
    Huzarski, Tomasz
    Pignata, Sandro
    Friedlander, Michael
    Baldoni, Alessandra
    Park-Simon, Tjoung-Won
    Tamura, Kenji
    Sonke, Gabe S.
    Lisyanskaya, Alla
    Kim, Jae-Hoon
    Filho, Elias Abdo
    Milenkova, Tsveta
    Lowe, Elizabeth S.
    Rowe, Phil
    Vergote, Ignace
    Pujade-Lauraine, Eric
    LANCET ONCOLOGY, 2021, 22 (05): : 620 - 631
  • [48] Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Final Analysis of a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial
    Poveda, Andres
    Floquet, Anne
    Ledermann, Jonathan A.
    Asher, Rebecca
    Penson, Richard T.
    Oza, Amit M.
    Korach, Jacob
    Huzarski, Tomasz
    Pignata, Sandro
    Friedlander, Michael
    Baldoni, Alessandra
    Park-Simon, Tjoung-Won
    Tamura, Kenji
    Sonke, Gabe S.
    Lisyanskaya, Alla
    Kim, Jae-Hoon
    Filho, Elias Abdo
    Milenkova, Tsveta
    Lowe, Elizabeth S.
    Rowe, Phil
    Vergote, Ignace
    Pujade-Lauraine, Eric
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2021, 76 (09) : 535 - 536
  • [49] Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial
    Tripathy, D
    Lichinitzer, M
    Lazarev, A
    MacLachlan, SA
    Apffelstaedt, J
    Budde, M
    Bergstrom, B
    ANNALS OF ONCOLOGY, 2004, 15 (05) : 743 - 750
  • [50] Ganaxolone Safety Profile in CDKL5 Deficiency Disorder: Results From a Phase 3 Randomized, Double-blind, Placebo-Controlled Trial
    Pestana-Knight, E.
    Rybak, E.
    Grachev, I
    Miller, I
    ANNALS OF NEUROLOGY, 2021, 90 : S132 - S133
12345